Status:
ACTIVE_NOT_RECRUITING
Evaluation of an Intervention to Reduce the Time to Treatment for TAVI Patients
Lead Sponsor:
University Hospital, Rouen
Conditions:
Aortic Valve Stenosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been ma...
Eligibility Criteria
Inclusion
- Patient over 18 years of age;
- Aortic stenosis
- Indication of TAVI
- Patient affiliated or benefiting from a health insurance scheme
- Patient having read and understood the information letter and having signed the consent form
Exclusion
- TAVI indication not retained
- Patient who are not fluent in French and have no one around them to translate,
- Patient who do not have access to the Internet (at home or in their immediate environment)
- Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the WHO) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ;
- Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curators
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent
Key Trial Info
Start Date :
October 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
748 Patients enrolled
Trial Details
Trial ID
NCT05237804
Start Date
October 26 2022
End Date
December 31 2025
Last Update
April 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brest University Hospital
Brest, France
2
CHU de Rouen
Rouen, France